-+ 0.00%
-+ 0.00%
-+ 0.00%

BIOMARIN PHARMACEUTICAL - EXPECTS $1.55 UNFAVORABLE IMPACT TO GAAP AND NON-GAAP DILUTED EPS FOR FULL YEAR 2026 - SEC FILING

Reuters·10/06/2026 20:23:39

Please log in to view news